Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Visfatin (NAMPT) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:NAMPT, Pre-B cell colony-enhancing factor, PBEF, Nicotinamide phosphoribosyltransferase, NAmPRTase, EC=2.4.2.12, Pre-B-cell colony-enhancing factor 1, PBEF1, NAMPT
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RAG004R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Applications

Serum

Sample Requirements

100 μl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

8 - 0,125 ng/ml

Limit of Detection

30 pg/ml

Intra-assay (Within-Run)

5,58%

Inter-assay (Run-to-Run)

6,24%

Spiking Recovery

98%

Dilution Linearity

85-105%

Physical Appearance

White lyophilized (freeze-dried) powder.

Note

More about Visfatin on BioVendor Scientific Blog

Summary

Research topic

Cytokines and chemokines and related molecules, Energy metabolism and body weight regulation

Summary

Excess adiposity is the most important risk in the development of insulin resistance and type 2 diabetes mellitus (T2DM). Adipose tissue produces several proteins (adipocytokines) such as leptin, adiponectin, resistin, tumor necrosis factor-α, and IL-6, that modulate insulin sensitivity and appear to play an important role in the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, and atherosclerosis. However, the mechanisms by which fat tissue induces insulin resistance and the role of adipocytokines in the pathogenesis of T2DM have not been well established. Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is a cytokine that is highly expressed in visceral fat and was originally isolated as a secreted factor that synergizes with IL-7 and stem cell factors to promote the growth of B cell precursors. Visfatin homologs have been identified in carp, invertebrate mollusks , and bacteria, as well as in vertebrates, including humans and the mouse. It has been postulated to play a role in innate immunity. Visfatin exerts insulin-mimetic effects that are dose-dependent and quantitatively similar to those of insulin in stimulating muscle and adipocyte glucose transport, and in inhibiting hepatocyte glucose production. Intravenous injection of recombinant visfatin in mice decreased plasma glucose in a dose-dependent fashion. In keeping with its insulin-mimetic effects, visfatin was as effective as insulin in reducing hyperglycemia in insulin-deficient diabetic mice. Visfatin was also found to be bound to and activate insulin receptor, causing receptor phosphorylation and the activation of downstream signaling molecules. However, visfatin and insulin did not compete for binding to the insulin receptor, indicating that the two proteins were recognized by different regions of the receptor. Thus, visfatin might play a role in glucose homeostasis and dysregulation in biosynthesis or signal transduction, and might contribute to the pathogenesis of diabetes.

Product References (12)

References

  • Lee YC, Lin CY, Chen YH, Chiu WC, Wang YY, Hsu C, Hu SC, Su YH, Yuan SF. Essential Role of Visfatin in Lipopolysaccharide and Colon Ascendens Stent Peritonitis-Induced Acute Lung Injury. Int J Mol Sci. 2019 Apr 4;20(7):1678. doi: 10.3390/ijms20071678. PubMed PMID: 30987270. PubMed CentralPMCID: PMC6480124. See more on PubMed
  • Mól N, Zasada M, Tomasik P, Klimasz K, Kwinta P. Evaluation of irisin and visfatin levels in very low birth weight preterm newborns compared to full term newborns-A prospective cohort study. PLoS One. 2018 Sep 27;13(9):e0204835. doi: 10.1371/journal.pone.0204835. eCollection 2018. PubMed PMID: 30261060. PubMed CentralPMCID: PMC6160155. See more on PubMed
  • Ochman M, Maruszewski M, Wojarski J, Żegleń S, Karolak W, Stanjek-Cichoracka A, Przybyłowski P, Zembala M, Kukla M. Serum Levels of Visfatin, Omentin and Irisin in Patients with End-Stage Lung Disease Before and After Lung Transplantation. Ann Transplant. 2017 Dec 26;22:761-768. doi: 10.12659/aot.904994. PubMed PMID: 29277835. PubMed CentralPMCID: PMC6248051. See more on PubMed
  • Rozmilowska I, Czyzewski D, Mazur B, Adamczyk-Sowa M. What is the role of adipokines in myasthenia gravis?. Ther Clin Risk Manag. 2018 Aug 28;14:1515-1525. doi: 10.2147/TCRM.S163966. eCollection 2018. PubMed PMID: 30214215. PubMed CentralPMCID: PMC6118871. See more on PubMed
  • Mousavi Z, Ganji A, Farrokh Tehrani D, Bahari A, EsmaeilZadeh A, Delghandi M. Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome. Med J Islam Repub Iran. 2017 May 28;31:28. doi: 10.18869/mjiri.31.28. eCollection 2017. PubMed PMID: 29445657. PubMed CentralPMCID: PMC5804438. See more on PubMed
  • Wyskida K, Franik G, Wikarek T, Owczarek A, Delroba A, Chudek J, Sikora J, Olszanecka-Glinianowicz M. The levels of adipokines in relation to hormonal changes during the menstrual cycle in young, normal-weight women. Endocr Connect. 2017 Nov;6(8):892-900. doi: 10.1530/EC-17-0186. Epub 2017 Oct 27. PubMed PMID: 29079670. PubMed CentralPMCID: PMC5704444. See more on PubMed
  • Razny U, Fedak D, Kiec-Wilk B, Goralska J, Gruca A, Zdzienicka A, Kiec-Klimczak M, Solnica B, Hubalewska-Dydejczyk A, Malczewska-Malec M. Carboxylated and undercarboxylated osteocalcin in metabolic complications of human obesity and prediabetes. Diabetes Metab Res Rev. 2017 Mar;33(3):e2862. doi: 10.1002/dmrr.2862. Epub 2016 Nov 7. PubMed PMID: 27667744. PubMed CentralPMCID: PMC6681168. See more on PubMed
  • Karpavicius A, Dambrauskas Z, Gradauskas A, Samuilis A, Zviniene K, Kupcinskas J, Brimas G, Meckovski A, Sileikis A, Strupas K. The clinical value of adipokines in predicting the severity and outcome of acute pancreatitis. BMC Gastroenterol. 2016 Aug 22;16(1):99. doi: 10.1186/s12876-016-0514-4. PubMed PMID: 27549125. PubMed CentralPMCID: PMC4994217. See more on PubMed
  • Wójcik K, Jabłonowska E, Omulecka A, Piekarska A. Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. World J Gastroenterol. 2014 Aug 14;20(30):10449-56. doi: 10.3748/wjg.v20.i30.10449. PubMed PMID: 25132761. PubMed CentralPMCID: PMC4130852. See more on PubMed
  • Samsam-Shariat SZ, Bolhasani M, Sarrafzadegan N, Najafi S, Asgary S. Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients. ARYA Atheroscler. 2014 Jul;10(4):218-26. PubMed PMID: 25258638. PubMed CentralPMCID: PMC4173313. See more on PubMed
  • Meier FM, Frommer KW, Peters MA, Brentano F, Lefèvre S, Schröder D, Kyburz D, Steinmeyer J, Rehart S, Gay S, Müller-Ladner U, Neumann E. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem. 2012 Aug 17;287(34):28378-85. doi: 10.1074/jbc.M111.312884. Epub 2012 Jul 5. PubMed PMID: 22767598. PubMed CentralPMCID: PMC3436531. See more on PubMed
  • Seo DI, So WY, Ha S, Yoo EJ, Kim D, Singh H, Fahs CA, Rossow L, Bemben DA, Bemben MG, Kim E. Effects of 12 weeks of combined exercise training on visfatin and metabolic syndrome factors in obese middle-aged women. J Sports Sci Med. 2011 Mar 1;10(1):222-6. eCollection 2011. PubMed PMID: 24149317. PubMed CentralPMCID: PMC3737906. See more on PubMed
Summary References (11)

References to Visfatin

  • Arner P. Visfatin--a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jan;91 (1):28-30
  • Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med Sci Monit. 2006 Jun;12 (6):RA112-9
  • Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005 Oct;54 (10):2911-6
  • Bottcher Y, Teupser D, Enigk B, Berndt J, Kloting N, Schon MR, Thiery J, Bluher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab. 2006 Jul;91 (7):2725-31
  • Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006 Jan;91 (1):295-9
  • Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006 Apr;49 (4):744-7
  • Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005 Jan 21;307 (5708):426-30
  • Haider DG, Mittermayer F, Schaller G, Artwohl M, Baumgartner-Parzer SM, Prager G, Roden M, Wolzt M. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab. 2006 Nov;291 (5):E885-90
  • Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006 Apr;91 (4):1578-81
  • Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006 Aug;91 (8):3165-70
  • Pfutzner A, Forst T. Comment on: Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M (2006) the release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49:1909-1914. Diabetologia. 2006 Nov;49 (11):2795; author reply 2796
Related Products Docs